NERV — Minerva Neurosciences Inc
NASDAQ · Healthcare · Biotechnology
$4.52
+$0.04 (+0.89%)
Minerva Neurosciences Inc (NERV) is a biotechnology company listed on NASDAQ. It is led by Remy Luthringer Ph.D., based in 1500 District Avenue, Burlington, MA, United States, 01803, with about 8 employees. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Net income was -$9.8M. NERV currently screens at market cap $12.4M and trailing P/E 2.2.
Use this NERV page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NERV quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NERV SEC filings page. Lician reads the product cache first so this HTML stays unique to Minerva Neurosciences Inc even when a live quote feed is slow.
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
NERV Key Statistics
Market Cap
$12.45M
Volume
114,277
Previous Close
$4.81
Day Range
$4.71 – $5.20
P/E Ratio
2.17
EPS
$0.19
Revenue
$0.00
Net Income
$1.44M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
8
NERV Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $1.44M | -$30.01M | -$32.11M | -$49.91M |
| EPS (Diluted) | $0.19 | -$4.61 | -$6.01 | -$9.35 |
Total Assets
$37.14M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$21.36M
Operating Cash Flow
-$19.55M
Free Cash Flow
$0.00
Minerva Neurosciences Inc Company Information
- Executive Chairman & CEO
- Remy Luthringer Ph.D.
- Headquarters
- 1500 District Avenue, Burlington, MA, United States, 01803
- Website
- www.minervaneurosciences.com
- Phone
- 617 600 7373
- IPO / Founded
- 2014-07-01
- Sector
- Healthcare
- Industry
- Biotechnology